leki
8

H. A^-methyI*2-nitroacetamide,

ASSAY

Dissolve 0.280 g in 35 ml of wałer R. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.2.20).

1 ml of 0.1 M sodium hydroxide is equivalent to 35.09 mg of CjjH^CIN^OjS.

STORAGE

In airtight Container, protected from UghL IMPURITIES

Specified impuriłies: A, B, C, D, E, F, G, H, I, J.

Other deteciable impuriłies: K.

CH₃

h₃c-n

A. A^A^r-bis[2-[[[5-((dimethylamino)methyl]furan-2-yl]methyl]sulphanyl]ethyl]-2-nitroethene-l,l-diamine,

I. 2,2^/-methylenebis[A42-{[[5-((dirnethylamino)methyl]furan-2-yl]methyl]sulphanyl]ethyl]-A^r-methyb2-nitroethene-l,l-diamine],

J. l,r-A4methylenebis(sulphanediyIethylene)]bis(A^r-methyl-2-nitroethene-l,l-diamine),

H

B. R = S-CH₂-CH₂-NH₂: 2-[[[5-{(dimethylamino)methyl]furan-2-yl]methyI]sulphanyl]ethanamine,

D. R = SCH₂-CH₂-NH-COCH₂-N0₂: Aq2-[[I5-[(dimethyl-amino)methyl]furan-2-yI]methyl]sulphanyl]ethyI]-2-ni-troacetamide,

F. R = OH: [5-[(dimethylamino)methyl]furan-2-yl]methanol,

K. A^-methyl-l-methylthio-2-nitroethenamine.

Działanie i zastosowanie.

Antagonista receptorów H₂ stosowany w chorobie wrzodowej żołądka i dwunastnicy oraz w zespołach przebiegających z nadmiernym wydzielaniem soku żołądkowego.

C. A^/’-[2-[[[5-{(dimethylamino)methyl]furan-2-

yllmethyllsulphinyljethylJ-A^-methyl^-nitroethene-l,!-

diamine,

E. A42-{[[54(dimethyloxidoamino)methyl]furan-2-

yl]methyl]sulphanyl]ethyl}-A^-methyl-2-nitroethene-l,l-

diamine,

H

G. 3-(methylamino)-5,6-dihydro-2//-l,4-thiazin-2-on6-oxirne,